Effect of different asthma treatments on risk of cold-related exacerbations

H. K. Reddel; C. Jenkins; S. Quirce; M. R. Sears; E. D. Bateman; P. M. O'Byrne; M. Humbert; R. Buhl; T. Harrison; G. G. Brusselle; A. Thorén; U. Sjöbring; S. Peterson; O. Östlund; G. S. Eriksson

doi:10.1183/09031936.00186510

Effect of different asthma treatments on risk of cold-related exacerbations

H. K. Reddel, C. Jenkins, S. Quirce, M. R. Sears, E. D. Bateman, P. M. O'Byrne, M. Humbert, R. Buhl, T. Harrison, G. G. Brusselle, A. Thorén, U. Sjöbring, S. Peterson, O. Östlund, G. S. Eriksson

Research output: Contribution to journal › Article › peer-review

Abstract

Common colds often trigger asthma exacerbations. The present study compared cold-related severe exacerbations during budesonide/formoterol maintenance and reliever therapy, and different regimens of maintenance inhaled corticosteroids (ICS), with or without long-acting β 2-agonists (LABA), and with as-needed short-acting β 2-agonists (SABA) or LABA. Reported colds and severe exacerbations (defined by oral corticosteroid use and/or hospitalisation/emergency room visit) were assessed for 12,507 patients during 6-12 months of double-blind treatment. Exacerbations occurring ≤14 days after onset of reported colds were analysed by a Poisson model. The incidence of colds was similar across treatments. Asthma symptoms and reliever use increased during colds. Budesonide/formoterol maintenance and reliever therapy reduced severe cold-related exacerbations by 36% versus pooled comparators plus SABA (rate ratio (RR) 0.64; p=0.002), and for individual treatment comparisons, by 52% versus the same maintenance dose of ICS/LABA (RR 0.48; p

Original language	English
Pages (from-to)	584-593
Number of pages	9
Journal	European Respiratory Journal
Volume	38
Issue number	3
DOIs	https://doi.org/10.1183/09031936.00186510
Publication status	Published - Sept 2011

Keywords

Asthma
Drug therapy
Exacerbations
Respiratory tract infections

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1183/09031936.00186510

http://erj.ersjournals.com/content/38/3/584.full.pdf+html

Cite this

Reddel, H. K., Jenkins, C., Quirce, S., Sears, M. R., Bateman, E. D., O'Byrne, P. M., Humbert, M., Buhl, R., Harrison, T., Brusselle, G. G., Thorén, A., Sjöbring, U., Peterson, S., Östlund, O., & Eriksson, G. S. (2011). Effect of different asthma treatments on risk of cold-related exacerbations. European Respiratory Journal, 38(3), 584-593. https://doi.org/10.1183/09031936.00186510

@article{783bfee2bfc6450b98f79b57f9298e75,

title = "Effect of different asthma treatments on risk of cold-related exacerbations",

abstract = "Common colds often trigger asthma exacerbations. The present study compared cold-related severe exacerbations during budesonide/formoterol maintenance and reliever therapy, and different regimens of maintenance inhaled corticosteroids (ICS), with or without long-acting β 2-agonists (LABA), and with as-needed short-acting β 2-agonists (SABA) or LABA. Reported colds and severe exacerbations (defined by oral corticosteroid use and/or hospitalisation/emergency room visit) were assessed for 12,507 patients during 6-12 months of double-blind treatment. Exacerbations occurring ≤14 days after onset of reported colds were analysed by a Poisson model. The incidence of colds was similar across treatments. Asthma symptoms and reliever use increased during colds. Budesonide/formoterol maintenance and reliever therapy reduced severe cold-related exacerbations by 36% versus pooled comparators plus SABA (rate ratio (RR) 0.64; p=0.002), and for individual treatment comparisons, by 52% versus the same maintenance dose of ICS/LABA (RR 0.48; p",

keywords = "Asthma, Drug therapy, Exacerbations, Respiratory tract infections",

author = "Reddel, {H. K.} and C. Jenkins and S. Quirce and Sears, {M. R.} and Bateman, {E. D.} and O'Byrne, {P. M.} and M. Humbert and R. Buhl and T. Harrison and Brusselle, {G. G.} and A. Thor{\'e}n and U. Sj{\"o}bring and S. Peterson and O. {\"O}stlund and Eriksson, {G. S.}",

year = "2011",

month = sep,

doi = "10.1183/09031936.00186510",

language = "English",

volume = "38",

pages = "584--593",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "3",

}

Reddel, HK, Jenkins, C, Quirce, S, Sears, MR, Bateman, ED, O'Byrne, PM, Humbert, M, Buhl, R, Harrison, T, Brusselle, GG, Thorén, A, Sjöbring, U, Peterson, S, Östlund, O & Eriksson, GS 2011, 'Effect of different asthma treatments on risk of cold-related exacerbations', European Respiratory Journal, vol. 38, no. 3, pp. 584-593. https://doi.org/10.1183/09031936.00186510

TY - JOUR

T1 - Effect of different asthma treatments on risk of cold-related exacerbations

AU - Reddel, H. K.

AU - Jenkins, C.

AU - Quirce, S.

AU - Sears, M. R.

AU - Bateman, E. D.

AU - O'Byrne, P. M.

AU - Humbert, M.

AU - Buhl, R.

AU - Harrison, T.

AU - Brusselle, G. G.

AU - Thorén, A.

AU - Sjöbring, U.

AU - Peterson, S.

AU - Östlund, O.

AU - Eriksson, G. S.

PY - 2011/9

Y1 - 2011/9

N2 - Common colds often trigger asthma exacerbations. The present study compared cold-related severe exacerbations during budesonide/formoterol maintenance and reliever therapy, and different regimens of maintenance inhaled corticosteroids (ICS), with or without long-acting β 2-agonists (LABA), and with as-needed short-acting β 2-agonists (SABA) or LABA. Reported colds and severe exacerbations (defined by oral corticosteroid use and/or hospitalisation/emergency room visit) were assessed for 12,507 patients during 6-12 months of double-blind treatment. Exacerbations occurring ≤14 days after onset of reported colds were analysed by a Poisson model. The incidence of colds was similar across treatments. Asthma symptoms and reliever use increased during colds. Budesonide/formoterol maintenance and reliever therapy reduced severe cold-related exacerbations by 36% versus pooled comparators plus SABA (rate ratio (RR) 0.64; p=0.002), and for individual treatment comparisons, by 52% versus the same maintenance dose of ICS/LABA (RR 0.48; p

AB - Common colds often trigger asthma exacerbations. The present study compared cold-related severe exacerbations during budesonide/formoterol maintenance and reliever therapy, and different regimens of maintenance inhaled corticosteroids (ICS), with or without long-acting β 2-agonists (LABA), and with as-needed short-acting β 2-agonists (SABA) or LABA. Reported colds and severe exacerbations (defined by oral corticosteroid use and/or hospitalisation/emergency room visit) were assessed for 12,507 patients during 6-12 months of double-blind treatment. Exacerbations occurring ≤14 days after onset of reported colds were analysed by a Poisson model. The incidence of colds was similar across treatments. Asthma symptoms and reliever use increased during colds. Budesonide/formoterol maintenance and reliever therapy reduced severe cold-related exacerbations by 36% versus pooled comparators plus SABA (rate ratio (RR) 0.64; p=0.002), and for individual treatment comparisons, by 52% versus the same maintenance dose of ICS/LABA (RR 0.48; p

KW - Asthma

KW - Drug therapy

KW - Exacerbations

KW - Respiratory tract infections

U2 - 10.1183/09031936.00186510

DO - 10.1183/09031936.00186510

M3 - Article

C2 - 21406510

SN - 0903-1936

VL - 38

SP - 584

EP - 593

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 3

ER -

Effect of different asthma treatments on risk of cold-related exacerbations

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this